Arbutus Biopharma Corp (ABUS): Investor presentation

Arbutus Biopharma updated its corporate presentation, reporting $104.6M in cash as of October 31, 2026. The company highlighted its hepatitis B pipeline, including 46% of Phase 2a patients achieving functional cure or discontinuing therapy, and plans for a potential Phase 2b imdusiran trial. AB-101 Phase 1 findings showed full PD-L1 receptor occupancy in 11 of 13 healthy subjects at 40 mg.

Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Geneva

Arbutus Biopharma reported Q3 2026 net income of $59.1M, or $0.30 per share, compared to a $7.7M net loss in Q3 2025. The company's cash and marketable securities increased to $337.5M by September 30, 2026, up from $91.5M at the end of 2025. The results reflect a shift from patent-settlement-related cash inflows and ongoing clinical development and patent litigation.

Arbutus Biopharma (ABUS) can now advance U.S. clinical trials for AB-101 after the FDA lifted its clinical hold. The oral PD-L1 inhibitor completed a Phase 1a/1b trial, showing good tolerability and some efficacy in cHBV patients. The company is evaluating next steps for development.

Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa

Arbutus Biopharma (ABUS) announced the FDA lifted its clinical hold on AB-101, an oral PD-L1 inhibitor for chronic HBV, allowing further U.S. clinical development. The company is assessing next steps. According to Arbutus, this enables additional U.S. clinical trials for AB-101.